Up to 510,000 Deaths Annually: The Overlooked "Snakebite" Crisis in the World

When you hear "the most dangerous animal in the world," what comes to mind?

Perhaps sharks, lions, crocodiles, or venomous cobras and black mambas. However, from the perspective of human harm, a significant health threat has long been overlooked, separate from the large carnivores that make headlines.

That threat is "snakebite."

According to a new study published in the medical journal "PLOS Medicine" in August 2026, at least about 2.1 million people worldwide are bitten by venomous snakes and suffer from the effects of the venom each year, with approximately 274,000 potentially dying.

Moreover, high estimates that consider regions with insufficiently recorded data suggest that cases with venom symptoms could reach about 7 million annually, with deaths possibly reaching about 513,000.

These figures significantly exceed the World Health Organization's (WHO) previous estimates of about 81,000 to 138,000 deaths annually.

Of course, this doesn't mean "510,000 people are definitely killed by snakes every year."

Rather, the wide range of these estimates itself tells the essence of the snakebite issue.

There are many regions in the world where even the number of people bitten by snakes is not accurately recorded.

Re-estimating global snakebite impacts after 17 years

The international research team conducting this study re-analyzed research on snakebites worldwide accumulated since 2007.

The study covered 79 countries. Researchers gathered studies on snakebites, venom intoxication, and deaths published by the end of March 2025, using not only hospital statistics but also surveys targeting local residents.

Furthermore, for regions with insufficient data, they used statistical models incorporating geographical and social conditions to make estimates.

This is the first large-scale estimation of the global burden of snakebites by the research team in about 17 years.

As a result of adding new data, the possibility of numerous unaccounted-for cases emerged.

The major issue is that many regions with frequent snakebites are concentrated in rural areas, not in cities with well-organized medical statistics.

People bitten by snakes during farm work may not go to the hospital. Or even if they want to, there may not be a hospital nearby.

Some may die on the way to a medical facility, which could take hours.

Some patients receive traditional treatments and do not visit medical institutions.

Such cases are likely to be omitted from national statistics and hospital records.

In other words, there may have been a large number of "uncounted patients" in the world's snakebite impacts so far.

About 45% of global impacts are in sub-Saharan Africa

The new study highlighted the significant burden in sub-Saharan Africa.

The research team's estimates suggest that this region alone could account for about 45% of the world's venom impacts and deaths.

South Asia also experiences a very high number of cases.

India is estimated to have the largest scale, with about 38,000 to 70,000 deaths annually. Nigeria, Pakistan, and the Democratic Republic of the Congo also bear a significant burden.

Why is the impact concentrated in specific regions?

The reason is not simply "because there are many venomous snakes."

A large agricultural population and people working daily in snake habitats are significant factors.

In areas around rice paddies, fields, pastures, and forests, human and snake living areas overlap.

Many people work barefoot or in sandals, and they may reach into grass when handling crops or firewood.

Snakes may also enter homes at night.

These environments are compounded by issues such as the distance to medical facilities, lack of transportation, treatment costs, and shortages of antivenoms.

Snakebites are not only "accidents with wildlife" but also social issues exacerbated by poverty and medical disparities.

The "most venomous snake" doesn't necessarily kill the most people

When it comes to venomous snakes, rankings like "what is the most venomous snake in the world" often attract attention.

A representative example is the inland taipan found in Australia.

It is known for its extremely potent venom but inhabits areas with few people, limiting human contact.

Therefore, having potent venom does not mean it causes the most deaths worldwide.

On the other hand, from the perspective of actual human harm, snakes of the genus Echis, such as saw-scaled vipers, are feared.

The original article also introduces a snake called "Gemeine Sandrasselotter" as a snake that may lead to numerous deaths.

These snakes are distributed in Africa, the Middle East, and South Asia and can be encountered near human dwellings and farmlands.

Their venom can cause severe blood coagulation abnormalities, leading to bleeding and organ damage.

This shows that "venom potency" and "danger to human society" are not the same.

Snakes with extremely high toxicity but little human encounter can result in fewer incidents than snakes living near farmlands where humans work daily.

Public health risks are determined not just by toxicity.

It's about the frequency of human contact and whether treatment can be received after being bitten.

Even if you survive, life changes—amputation, blindness, kidney damage

The snakebite issue cannot be understood by looking at the number of deaths alone.

Symptoms vary greatly depending on the nature of the venom.

If the venom affects the nerves, muscles may become paralyzed, making it impossible to breathe independently.

Venom that destroys blood coagulation systems can prevent blood clotting, causing severe internal bleeding.

Some patients may suffer kidney damage and require dialysis.

If the tissue at the bitten area becomes necrotic, amputation may be necessary to prevent infection or gangrene.

Estimates related to the research introduced in the original article suggest that about 825,000 people may suffer severe disabilities annually due to snakebites.

And the issue of "after surviving" is extremely serious.

Those most vulnerable are agricultural workers and manual laborers.

If the breadwinner of a family loses a leg or arm, it doesn't end with just a medical issue for the individual.

They may no longer be able to continue working, resulting in the loss of income for the entire family.

Some families may incur debt to pay for treatment or sell livestock and land.

A single snakebite can plunge a family into long-term poverty.

The WHO's positioning of snakebites as a significant issue of "neglected tropical diseases" is due to this large social impact.

Why do hundreds of thousands die annually despite the existence of antivenoms?

What further highlights the tragedy of snakebites is the fact that effective treatments already exist.

If the appropriate antivenom is administered at the right time after a venomous snakebite, many patients could potentially be saved.

The WHO also positions high-quality antivenoms as central medicines in snakebite treatment.

Yet people still die.

Why is that?

One of the biggest issues is that "the existence of a drug" and "the drug being in front of the patient" are entirely different matters.

Snake venom varies by type and region.

Therefore, antivenoms tailored to the snakes inhabiting that region must be secured, properly manufactured, transported, and stored.

However, in rural areas with high snakebite incidences, necessary antivenoms may not be available at clinics.

Even if a major hospital in a city has stock, if it takes hours for the patient to arrive there, it may not be in time to save their life.

The WHO itself states that many deaths and severe aftereffects from snakebites can be prevented by improving access to safe and effective antivenoms.

In other words, some of the massive deaths currently occurring are not due to the power of the snakes themselves but are created by a "system that cannot deliver treatment."

On social media, "Why is this not getting more attention?"

Regarding the study announced on August 25, 2026, it is difficult to aggregate global social media reactions from general users at this point.

Meanwhile, on social media in 2026 regarding the snakebite issue itself, very distinctive discussions have been ongoing.

Particularly noticeable is the criticism that "there is too little research funding and social interest relative to the scale of the impact."

A representative from VenomAid Diagnostics, which researches snakebite diagnostic technology, made a very striking post on LinkedIn comparing the production cost of the Hollywood movie "Snakes on a Plane" to global snakebite research and development costs.

Through a comparison showing that the movie's production cost and global investment in snakebite research were roughly the same, the post questions whether this level of investment is appropriate for an issue that causes numerous deaths and disabilities each year.

Of course, one cannot simply compare movie production costs to medical research funding.

However, as a message that attracts attention on social media, this comparison symbolizes how much snakebites have become a "forgotten issue."

Posts by public health officials in Africa on LinkedIn repeatedly highlight issues such as the supply chain for antivenoms, lack of training for medical personnel, and weak case monitoring.

There is a strong recognition that it is not just about "creating a new drug," but improving the entire process from when a patient is bitten to when they receive treatment.

Emergency transportation, education for local residents, diagnosis, antivenom inventory management, and medical staff training.

The focus in expert communities on social media is shifting to these on-the-ground challenges.

On Reddit, there is also hope for "new antivenoms"

Meanwhile, on Reddit, where general users participate, there is also hope for research into new generations of antivenoms.

In August 2026, a study attempting to develop new antivenoms inspired by the mechanism by which snakes themselves possess certain resistance to their own venom was shared as science news.

Related posts gathered support on the scale of hundreds of votes.

This research suggests the possibility of using substances in the blood serum of venomous snakes themselves to create antivenoms that can address multiple types of venom.

Traditional antivenoms have the major challenge of needing to be tailored to specific snakes or regions.

If, in the future, a treatment that can address more snake venoms, is easier to manufacture, and is easier to store and transport emerges, it could significantly improve survival rates in rural areas.

The background to the hope for new antivenoms on social media is likely the recognition that snakebites are not "incurable diseases" but "deaths that can be reduced by improving technology and social systems."

New snakebite measures with a £6.25 million investment

Efforts to raise awareness of snakebites are also beginning.

In June 2026, Wellcome, known for supporting medical research, launched the "Snakebite Innovation Prize."

The total amount is £6.25 million.

The goal is not just to discover new antivenoms.

It is to solicit ideas from around the world to solve various barriers preventing patients from reaching treatment, such as regional responses immediately after being bitten, emergency transportation, referrals to appropriate medical facilities, diagnosis, and antivenom supply.

This point is very important.

Reducing deaths from snakebites requires more than just cutting-edge drugs.

For example, a simple ambulance system to quickly transport patients in rural areas could save hundreds of lives.

A system to share which hospitals have antivenom stock could also be useful.

Training medical personnel and educating residents on proper first aid are also important.

What is needed is not just a "super antivenom," but a system that ensures continuity from the moment a snakebite occurs to the end of treatment.

WHO aims to halve deaths and disabilities by 2030

In 2019, the WHO launched an international strategy to reduce deaths and disabilities from snakebites by 50% by 2030.

The main pillars are education for local communities, ensuring safe and effective treatments, strengthening healthcare systems, and international cooperation and research investment.

Snakebite prevention does not require extremely advanced technology.

Wearing sturdy shoes in dangerous areas.

Using lights when walking outdoors at night.

Not increasing the number of mice, which are prey for snakes, around homes.

Avoiding reaching into grass carelessly during farm work.